文献速递临床试验与 GCP流行病学与生物统计

导管消融与抗心律失常药物治疗对心房颤动患者死亡率、卒中、出血和心脏骤停的影响:CABANA随机临床试验

Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

CABANA多中心随机试验纳入2204例症状性心房颤动患者,比较导管消融与药物治疗。中位随访48.5个月,主要复合终点(死亡、致残性卒中、严重出血或心脏骤停)两组无显著差异(8.0% vs 9.2%,HR 0.86,P=0.30);全因死亡无显著差异,但消融组死亡或心血管住院及房颤复发风险较低。

要点

  • 导管消融未显著降低主要复合终点(死亡、致残性卒中、严重出血或心脏骤停),HR 0.86,P=0.30。
  • 全因死亡两组无显著差异(5.2% vs 6.1%,HR 0.85,P=0.38)。
  • 消融组房颤复发率49.9% vs 药物组69.5%(HR 0.52,P<0.001)。

核心结论

  • 在心房颤动患者中,与药物治疗相比,导管消融策略未显著降低死亡、致残性卒中、严重出血或心脏骤停的主要复合终点。
  • 导管消融的估计治疗效果受到低于预期的事件率和治疗交叉的影响,在解读试验结果时应予以考虑。

研究设计与样本

  • CABANA试验为研究者发起的开放标签多中心随机试验,涉及10个国家126个中心。
  • 2009年11月至2016年4月共纳入2204例症状性心房颤动患者,年龄65岁及以上或65岁以下且具有1项及以上卒中危险因素,随访至2017年12月31日。
  • 导管消融组1108例接受肺静脉隔离,并由中心研究者决定附加消融操作;药物组1096例接受指南指导下的标准节律和/或心率控制药物。

主要发现

  • 中位随访48.5个月,主要终点在消融组发生8.0%(n=89),药物组9.2%(n=101),HR 0.86(95%CI 0.65-1.15),P=0.30。
  • 全因死亡消融组5.2% vs 药物组6.1%,HR 0.85(95%CI 0.60-1.21),P=0.38。
  • 死亡或心血管住院消融组51.7% vs 药物组58.1%,HR 0.83(95%CI 0.74-0.93),P=0.001。
  • 房颤复发消融组49.9% vs 药物组69.5%,HR 0.52(95%CI 0.45-0.60),P<0.001。
  • 随机分组中,消融组1006例(90.8%)接受了手术;药物组301例(27.5%)最终接受了导管消融。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 导管消融的估计治疗效果受到低于预期的事件率和治疗交叉的影响,在解读试验结果时应予以考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Catheter ablation is effective in restoring sinus rhythm in atrial fibrillation (AF), but its effects on long-term mortality and stroke risk are uncertain. OBJECTIVE: To determine whether catheter ablation is more effective than conventional medical therapy for improving outcomes in AF. DESIGN, SETTING, AND PARTICIPANTS: The Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation trial is an investigator-initiated, open-label, multicenter, randomized trial involving 126 centers in 10 countries. A total of 2204 symptomatic patients with AF aged 65 years and older or younger than 65 years with 1 or more risk factors for stroke were enrolled from November 2009 to April 2016, with follow-up through December 31, 2017. INTERVENTIONS: The catheter ablation group (n = 1108) underwent pulmonary vein isolation, with additional ablative procedures at the discretion of site investigators. The drug therapy group (n = 1096) received standard rhythm and/or rate control drugs guided by contemporaneous guidelines. MAIN OUTCOMES AND MEASURES: The primary end point was a composite of death, disabling stroke, serious bleeding, or cardiac arrest. Among 13 prespecified secondary end points, 3 are included in this report: all-cause mortality; total mortality or cardiovascular hospitalization; and AF recurrence. RESULTS: Of the 2204 patients randomized (median age, 68 years; 37.2% female; 42.9% had paroxysmal AF and 57.1% had persistent AF), 89.3% completed the trial. Of the patients assigned to catheter ablation, 1006 (90.8%) underwent the procedure. Of the patients assigned to drug therapy, 301 (27.5%) ultimately received catheter ablation. In the intention-to-treat analysis, over a median follow-up of 48.5 months, the primary end point occurred in 8.0% (n = 89) of patients in the ablation group vs 9.2% (n = 101) of patients in the drug therapy group (hazard ratio [HR], 0.86 [95% CI, 0.65-1.15]; P = .30). Among the secondary end points, outcomes in the ablation group vs the drug therapy group, respectively, were 5.2% vs 6.1% for all-cause mortality (HR, 0.85 [95% CI, 0.60-1.21]; P = .38), 51.7% vs 58.1% for death or cardiovascular hospitalization (HR, 0.83 [95% CI, 0.74-0.93]; P = .001), and 49.9% vs 69.5% for AF recurrence (HR, 0.52 [95% CI, 0.45-0.60]; P < .001). CONCLUSIONS AND RELEVANCE: Among patients with AF, the strategy of catheter ablation, compared with medical therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest. However, the estimated treatment effect of catheter ablation was affected by lower-than-expected event rates and treatment crossovers, which should be considered in interpreting the results of the trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00911508.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019. PMID: 30874766. doi:10.1001/jama.2019.0693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。